Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an update.
Botanix Pharmaceuticals Limited has announced the appointment of Dr. Patricia Walker as a director, effective from August 25, 2025. Dr. Walker holds significant interests in the company with a total of 9,000,000 unquoted options across various exercise prices and expiration dates. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and enhancing its market position.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of dermatology and antimicrobial products. The company is known for its innovative treatments and solutions aimed at addressing unmet medical needs in skin health and infection control.
Average Trading Volume: 15,306,475
Technical Sentiment Signal: Sell
Current Market Cap: A$294.2M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.